Status:
NOT_YET_RECRUITING
Intravenous Tranexamic Acid
Lead Sponsor:
Ain Shams University
Conditions:
Obese Patients
Obese Patients With Bariatric Surgery
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Tranexamic acid is a promising option for minimizing blood loss in high-risk bariatric surgery patients, particularly in those with obesity, diabetes, and other comorbidities. When used appropriately,...
Detailed Description
The impact of TXA in high-risk individuals undergoing bariatric surgery is of increasing interest, especially given the inherent risks of bleeding and complications associated with these procedures. B...
Eligibility Criteria
Inclusion
- High-risk patients, with obesity, BMI more than 45,
- Patients with Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.
Exclusion
- patients with active thromboembolic disorders.
- Patients with preexisting renal dysfunction,
Key Trial Info
Start Date :
October 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2026
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT07192640
Start Date
October 15 2025
End Date
March 30 2026
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Salman Specialist Hospital, Hail, KSA
Hail, Saudi Arabia, 6539307